Replies to post #196739 on Biotech Values

[DewDiligence]

(AGN/RVNC)—FDA approves (private) Merz Pharma’s Xeomin for upper-limb spasticity:

http://finance.yahoo.com/news/merz-north-america-announces-fda-190700726.html

Xeomin is a direct competitor of AGN’s Botox, but it has captured little market share in medical applications—and even less share in cosmetic applications.